Literature DB >> 17786449

Prevalence and factors associated with dyslipoproteinemias in Brazilian systemic lupus erythematosus patients.

Claudia R L Cardoso1, Flávio V Signorelli, Jose A Papi, Gil F Salles.   

Abstract

To determine the prevalence of dyslipoproteinemias and their related factors in a Brazilian systemic lupus erythematosus (SLE) population, fasting lipids were measured in 185 female SLE outpatients. Age, BMI, smoking, post-menopausal status, presence of diabetes and hypertension, SLE duration, number of ARA criteria, drug treatment and disease activity (by SLEDAI) were registered. Statistics included uni and multivariate logistic regression. Eighty-nine patients (48.1%) had hypercholesterolemia, 55 (29.7%) had hypertriglyceridemia and 109 (58.9%) had either. On multivariate analysis, 24-h proteinuria (OR = 2.08, 95% CI: 1.11-3.88), BMI (OR = 1.08, 95% CI: 1.01-1.16) and post-menopausal status (OR = 2.48, 95% CI: 1.25-4.92) were associated with hypercholesterolemia. Disease activity was related to low HDL-cholesterol (OR = 2.59, 95% CI: 1.20-5.58) and, in pre-menopausal patients, also to hypertriglyceridemia (OR = 1.16, 95% CI: 1.03-1.30). Antimalarial use was protective for hypertriglyceridemia (OR = 0.44, 95% CI: 0.22-0.90). In conclusion, the increased prevalence of dyslipoproteinemias is due to proteinuria, obesity and SLE activity. Antimalarials have beneficial effect on lipid profile that may be due to reduction in disease activity.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17786449     DOI: 10.1007/s00296-007-0447-x

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  21 in total

1.  Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III).

Authors: 
Journal:  JAMA       Date:  2001-05-16       Impact factor: 56.272

2.  Dyslipoproteinemias in systemic lupus erythematosus: influence of disease, activity, and anticardiolipin antibodies.

Authors:  E F Borba; E Bonfá
Journal:  Lupus       Date:  1997       Impact factor: 2.911

3.  Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus.

Authors:  J M Esdaile; M Abrahamowicz; T Grodzicky; Y Li; C Panaritis; R du Berger; R Côte; S A Grover; P R Fortin; A E Clarke; J L Senécal
Journal:  Arthritis Rheum       Date:  2001-10

4.  Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study.

Authors:  S Manzi; E N Meilahn; J E Rairie; C G Conte; T A Medsger; L Jansen-McWilliams; R B D'Agostino; L H Kuller
Journal:  Am J Epidemiol       Date:  1997-03-01       Impact factor: 4.897

5.  Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE.

Authors:  C Bombardier; D D Gladman; M B Urowitz; D Caron; C H Chang
Journal:  Arthritis Rheum       Date:  1992-06

6.  Lipid and lipoprotein levels in premenopausal systemic lupus erythematosus patients.

Authors:  F Formiga; J F Meco; X Pinto; J Jacob; I Moga; R Pujol
Journal:  Lupus       Date:  2001       Impact factor: 2.911

7.  The cholesterol lowering effect of antimalarial drugs is enhanced in patients with lupus taking corticosteroid drugs.

Authors:  P Rahman; D D Gladman; M B Urowitz; K Yuen; D Hallett; I N Bruce
Journal:  J Rheumatol       Date:  1999-02       Impact factor: 4.666

8.  Effect of prednisone and hydroxychloroquine on coronary artery disease risk factors in systemic lupus erythematosus: a longitudinal data analysis.

Authors:  M Petri; C Lakatta; L Magder; D Goldman
Journal:  Am J Med       Date:  1994-03       Impact factor: 4.965

9.  Risk factors for coronary artery disease in patients with systemic lupus erythematosus.

Authors:  M Petri; S Perez-Gutthann; D Spence; M C Hochberg
Journal:  Am J Med       Date:  1992-11       Impact factor: 4.965

10.  Elevated triglycerides and low levels of high-density lipoprotein as markers of disease activity in association with up-regulation of the tumor necrosis factor alpha/tumor necrosis factor receptor system in systemic lupus erythematosus.

Authors:  Elisabet Svenungsson; Iva Gunnarsson; Guo-Zhong Fei; Ingrid E Lundberg; Lars Klareskog; Johan Frostegård
Journal:  Arthritis Rheum       Date:  2003-09
View more
  8 in total

Review 1.  The role of antimalarial agents in the treatment of SLE and lupus nephritis.

Authors:  Senq-J Lee; Earl Silverman; Joanne M Bargman
Journal:  Nat Rev Nephrol       Date:  2011-10-18       Impact factor: 28.314

2.  Excess weight and associated risk factors in patients with systemic lupus erythematosus.

Authors:  Fabiana de Miranda Moura dos Santos; Mariane Curado Borges; Rosa Weiss Telles; Maria Isabel T D Correia; Cristina Costa Duarte Lanna
Journal:  Rheumatol Int       Date:  2012-04-22       Impact factor: 2.631

Review 3.  Lipid Metabolism: Immune Regulation and Therapeutic Prospectives in Systemic Lupus Erythematosus.

Authors:  Wei Sun; Pengchong Li; Jianping Cai; Jie Ma; Xuan Zhang; Yong Song; Yudong Liu
Journal:  Front Immunol       Date:  2022-03-18       Impact factor: 7.561

Review 4.  Hydroxychloroquine in systemic lupus erythematosus: overview of current knowledge.

Authors:  Alina Dima; Ciprian Jurcut; François Chasset; Renaud Felten; Laurent Arnaud
Journal:  Ther Adv Musculoskelet Dis       Date:  2022-02-14       Impact factor: 5.346

Review 5.  High-Density Lipoprotein in Lupus: Disease Biomarkers and Potential Therapeutic Strategy.

Authors:  Sang Yeop Kim; Minzhi Yu; Emily E Morin; Jukyung Kang; Mariana J Kaplan; Anna Schwendeman
Journal:  Arthritis Rheumatol       Date:  2019-11-26       Impact factor: 10.995

6.  Cardiovascular disease in latin american patients with systemic lupus erythematosus: a cross-sectional study and a systematic review.

Authors:  Jenny Amaya-Amaya; Juan Camilo Sarmiento-Monroy; Julián Caro-Moreno; Nicolás Molano-González; Rubén D Mantilla; Adriana Rojas-Villarraga; Juan-Manuel Anaya
Journal:  Autoimmune Dis       Date:  2013-11-03

Review 7.  Cardiovascular involvement in autoimmune diseases.

Authors:  Jenny Amaya-Amaya; Laura Montoya-Sánchez; Adriana Rojas-Villarraga
Journal:  Biomed Res Int       Date:  2014-07-22       Impact factor: 3.411

8.  Reduction in SLEDAI is associated with improved arterial stiffness in systemic lupus erythematosus.

Authors:  Tian Du; Haiyu Pang; Faming Ding; Yicong Ye; Mengtao Li; Xufei Yang; Yang Zhang; Xiaofeng Zeng; Shuyang Zhang
Journal:  Medicine (Baltimore)       Date:  2020-11-20       Impact factor: 1.817

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.